Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib

Novartis presented Phase III study results for remibrutinib, showing a 35.2% and 31.2% reduction in annual relapse rates for relapsing multiple sclerosis compared to Sanofi's Aubagio. The drug showed a favorable safety profile, potentially aiding market competition, according to STAT News.

Novartis's U.S. shares dropped 4.5% after presenting MS pill trial data showing relapse rate reductions of 35.2% and 31.2% vs. Sanofi's Aubagio, below Roche's 51.1%-58.5% with fenebrutinib. No liver safety issues were observed. Analysts expected at least parity in efficacy. Novartis aims for long-term disease management.

Novartis' MS drug remibrutinib reduced relapse rates by 35.2% and 31.2% in Phase 3 trials compared to Sanofi's Aubagio, according to data presented at a conference. The drug showed a cleaner safety profile but less efficacy than Roche's rival treatment.

Novartis reported that its experimental MS pill, remibrutinib, showed significant reductions in symptom flare-ups (35.2% and 31.2%) compared to Sanofi's Aubagio in late-stage trials. The drug demonstrated a favorable safety profile with no observed liver safety signals, according to the company.

Novartis' remibrutinib showed superior results in Phase III RMS trials, reducing relapses and disease progression vs. teriflunomide. The drug demonstrated a robust safety profile with no liver safety signals. Novartis plans global regulatory approvals.

Novartis (NVS) reported positive Phase 3 trial results for remibrutinib, showing superior relapse control and delayed disease progression in relapsing multiple sclerosis. The drug reduced annualized relapse rate by 35.2% and 31.2% in two trials, with no liver safety signal. Results were presented at MSToronto2026 and published in The Lancet.